Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARS1 | P26639 | 2/20 | 1.00 |
| ▸ | IARS1 | P41252 | 1/20 | 0.86 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.82 |
| ▸ | SARS1 | P49591 | 1/20 | 0.80 |
| ▸ | MARS1 | P56192 | 1/20 | 0.76 |
| ▸ | RARS1 | P54136 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316150 | 1.00 | TARS1 (1.00) | TARS1IARS1LARS1SARS1MARS1 | |
| Alasa SCHEMBL21067643 | 0.93 | TARS1 (0.87) | TARS1IARS1LARS1SARS1MARS1 | |
| Alasa SCHEMBL29531843 | 0.93 | TARS1 (0.87) | TARS1IARS1LARS1SARS1MARS1 | |
| Alasa SCHEMBL4320823 | 0.93 | TARS1 (0.87) | TARS1IARS1LARS1SARS1MARS1 | |
| SCHEMBL28937745 | 0.93 | IARS1 (1.00) | TARS1IARS1LARS1SARS1 | |
| Leusa SCHEMBL29562511 | 0.90 | LARS1 (1.00) | TARS1IARS1LARS1SARS1MARS1 | |
| SCHEMBL21067959 | 0.89 | SARS1 (1.00) | TARS1IARS1LARS1SARS1MARS1 | |
| SCHEMBL21068060 | 0.89 | SARS1 (0.87) | TARS1IARS1LARS1SARS1MARS1 | |
| SCHEMBL3187665 | 0.89 | SARS1 (0.87) | TARS1IARS1LARS1SARS1MARS1 | |
| SCHEMBL3187637 | 0.89 | SARS1 (0.87) | TARS1IARS1LARS1SARS1MARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |